| Literature DB >> 11406577 |
J M van den Elsen1, D A Kuntz, D R Rose.
Abstract
Golgi alpha-mannosidase II, a key enzyme in N-glycan processing, is a target in the development of anti- cancer therapies. The crystal structure of Drosophila Golgi alpha-mannosidase II in the absence and presence of the anti-cancer agent swainsonine and the inhibitor deoxymannojirimycin reveals a novel protein fold with an active site zinc intricately involved both in the substrate specificity of the enzyme and directly in the catalytic mechanism. Identification of a putative GlcNAc binding pocket in the vicinity of the active site cavity provides a model for the binding of the GlcNAcMan(5)GlcNAc(2) substrate and the consecutive hydrolysis of the alpha1,6- and alpha1,3-linked mannose residues. The enzyme-inhibitor interactions observed provide insight into the catalytic mechanism, opening the door to the design of novel inhibitors of alpha-mannosidase II.Entities:
Mesh:
Substances:
Year: 2001 PMID: 11406577 PMCID: PMC150216 DOI: 10.1093/emboj/20.12.3008
Source DB: PubMed Journal: EMBO J ISSN: 0261-4189 Impact factor: 11.598